Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Credevo Pte. Ltd. Singapore

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.
Website:
https://credevo.com
Looking for
Headquartner in China
No
Biotech/Pharma Category
Dr Kshitij Soni
LinkedIn logo CEO 
Functionality
Management

Crossject USA Inc United States

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.
Website:
www.crossject.com
Company Size (Fulltime employees)
51-200
Year of foundation
2001
Stock Market and Ticker/Symbol/Number
ALCJ
Looking for
Funding Status
publicly traded
Headquartner in China
No
Plan in China
Partner with a mid-large pharma partner with sales capabilities in China, North America and Europe
Don Zinn
VP US Business 
Functionality
Business Development

Curevo Vaccine United States

Curevo is a clinical stage company dedicated to bringing next generation vaccines that offer effectiveness, safety, tolerability, and production advantages to the market, quickly and efficiently.
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.
Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available.
Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research and GC Pharma.
Curevo's lead product, a Zoster (Shingles) Vaccine, has completed Phase I and shown promising results. We are targeting a unique position in the $20B (by 2030) Varicella Zoster Virus vaccine market.
Website:
www.curevovaccine.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Raising Series-A
Headquartner in China
No
Plan in China
As a premium and high margin segment, the shingles vaccine market represents a significant opportunity for local, regional, or global players.
George Simeon
CEO 
Functionality
Management

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Website:
www.d2mbio.com
Looking for
Headquartner in China
No
Nan Bing
CEO 
Functionality
Management

Dawn Biopharmaceuticals Inc. United States

Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.

(Please note that the website is pending.)

Website:
dawnbio.net
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Looking for
Please specify your partnering goal
Strategic pharmaceutical or capital partner to accompany into Pre-IND and clinical trials.
Funding Status
Initial round
Headquartner in China
No
Plan in China
Open to partnerships with Chinese firms that have a proprietary small molecule or biodrug that could be encoded into our platform with the benefits of wider scope of applications, tumor-centric molecular therapeutic delivery, avoidance of peripheral (extra tumoral) actions and effects, and vectoring of high payload(s) for multi-arming.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Gordon Lee
Founder 
Functionality
Management

Deutsche Bank AG London United Kingdom

Deutsche Bank is the largest bank in Germany and one of only 4 Depositary Receipt banks able to list Life Sciences and Medtech companies on US exchanges using ADRs.
Website:
www.dbadr.com
Company Size (Fulltime employees)
5000+
Year of foundation
1886
Looking for
Please specify your partnering goal
Meet companies hoping to list and raise capital in the US
Headquartner in China
No
Joseph Oakenfold
Vice President 
Functionality
Business Development

DIMITAR DIMITROV Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET

Website:
http://micar21.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Drug Discovery
Funding Status
raising
Now raising (In USD)
2500000
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Investment Focus
Oncology project
Slides Deck
(pdf, 939.67KB)
CEO 
Functionality
Management

DivaOra Group Russia

Manufacturing, whole sale innovation product EYEIMPROVER.com - the stimulator for the eyes
Website:
www.eyeimrpver.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Funding Status
investment, strategy investor
Headquartner in China
No
Plan in China
We want move our business from CHINA. We searshin investment and we are ready for relocation.
Olga Oshurkova
CEO & Owner 
Functionality
Management

Drive Therapeutics, LLC United States

Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.
Website:
drivetherapeutics.com
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Looking for
Please specify your partnering goal
Looking for a partner to move the program forward to get proof of concept
Funding Status
Seed Stage
Now raising (In USD)
600k- 2.0 MM
Headquartner in China
No
Plan in China
We feel that our product would be very successful in the China market. A co-development deal would be ideal.
Biotech/Pharma Category
Ryan Quick
Co-founder and COO 
Functionality
Management

East Continent

Distributer for pharmaceutical products
Website:
snzimmo@hotmail.com
Company Size (Fulltime employees)
1-10
Year of foundation
5
Looking for
Please specify your partnering goal
To be an agent in Saudi market
Headquartner in China
No
Suhail Zimmo
Operations Manager 
Functionality
Management